The year's new drugs and biologics--2007.
This annual article presents new drugs and biologics that were launched or approved for the first time during the previous year. In 2007, 30 new medicines--this figure includes both drugs and biologics for therapeutic use as well as new diagnostic agents--reached their first markets. Drug repositioning continues to have a significant impact, with line extensions (new indications, new formulations and new combinations of previously marketed products) accounting for 45% of the new medicines launched in 2007. Several new features were introduced last year, and have been maintained due to a high level of interest from readers: a deeper insight into the three first-in-class drugs launched for the first time last year, providing a better understanding of their novel mechanisms of action; an analysis of the discovery and development periods for the year's new products; a comprehensive overview of drug repositioning as a strategy for extending the life span of medicines; and an analysis of the market for these new medicines. We also provide a brief glimpse at selected drugs and biologics which could reach their first markets in the foreseeable future.
Graul
A I
AI
Prous
J R
JR
Barrionuevo
M
M
Bozzo
J
J
Castaner
R
R
Cruces
E
E
Revel
L
L
Rosa
E
E
Serradell
N
N
Sorbera
L A
LA
D001688:Biological Products; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics / Q000639:trends; D006801:Humans; D004364:Pharmaceutical Preparations; D010600:Pharmacology / Q000639:trends
D001688:Biological Products; D004364:Pharmaceutical Preparations